Amarin Corporation plc announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarins Executive Vice President and President of the U.S. Business, as Interim Chief Executive Officer (CEO), effective immediately. Mr. Berg joined Amarin in November 2012 and has more than 25 years of biopharmaceutical industry experience. Mr. Berg initially served as Amarins Vice President, Marketing and Managed Care.

He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018. Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as Vice President of Marketing and Sales at Kos Pharmaceuticals (Kos), where he was instrumental in driving annual revenues approaching $1 billion.

Mr. Berg worked at Kos until it was acquired by Abbott Laboratories in December 2006 for $3.7 billion.